2010-019670-32: Pharmacokinetics and Safety of Human Pasteurised C1-Inhibitor Concentrate (Berinert/CE1145) in Subjects with Congenital C1-INH Deficiency. Studio della farmacocinetica e della sicurezza del C1-Inibitore concentrato pasteurizzato umano (Berinert/CE1145) in soggetti con deficienza congenita di C1-INH. |
|
|
| Ongoing | 3 | 3 | Europe | Powder and solvent for solution for injection, BERINERT*IV FL 500U+FL 10ML | AZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE), CSL Behring | Hereditary Angioedema (HAE) angioedema ereditario, Hereditary Angioedema (HAE) angioedema ereditario, Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
2020-002225-29: Evaluation of the effects of bradykinin antagonists on pulmonary manifestations of COVID-19 infections. Evaluation des effets des antagonistes de la bradykinine sur les manifestations pulmonaires des infections à COVID-19. |
|
|
| Not yet recruiting | 2 | 45 | Europe | Concentrate and solvent for solution for injection/infusion, Solution for injection in pre-filled syringe, BERINERT, FIRAZYR | Groupement de Coopération Sanitaire Ramsay Générale de Santé pour l’Enseignement et la Recherche, Groupement de Coopération Sanitaire Ramsay Générale de Santé pour l’Enseignement et la Recherche | COVID positive patients with respiratory impairment Patients COVID + avec atteinte respiratoire, COVID positive patients with respiratory impairment Patients COVID + avec atteinte respiratoire, Diseases [C] - Virus Diseases [C02] | | | | |
| Active, not recruiting | 1/2 | 45 | US | Berinert, C1 Esterase Inhibitor (C1INH), Placebo, Normal Saline | Cedars-Sinai Medical Center, OneLegacy Foundation | End Stage Renal Disease, Chronic Kidney Diseases | 07/22 | 03/24 | | |